Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring

Figure 3 The receiver operating characteristic curves, calculated area under the curves, and sensitivity and specificity values of the four DNA methylation biomarkers in the plasma of patients with cholangiocarcinoma and the receiver operating characteristic curves for circulating tumor cells to assess cholangiocarcinoma progression. A: The receiver operating characteristic (ROC) of SHOX2; B: ROC of HOXA9; C: ROC of RASSF1A; D: ROC of SEPTIN9; E: ROC of circulating tumor cell for progression. The ROC curves and resulting area under the curve (AUC) for 96 patients with cholangiocarcinoma are depicted. AUC-SHOX2 = 0.799 (95%CI: 0.724-0.874), AUC-SEPTIN9 = 0.713 (95%CI: 0.632-0.795), AUC-RASSF1A = 0.765 (95%CI: 0.689-0.841), AUC-HOXA9 = 0.777 (95%CI: 0.705-0.850). AUC-circulating tumor cells = 0.653 (95%CI: 0.533-0.774). ROC: The receiver operating characteristic; CTC: Circulating tumor cell.